undamentalytics Newsletter
Sign in

C4 Therapeutics, Inc. income statement

In fiscal 2025, C4 Therapeutics, Inc. reported revenue of $35.9m, up 1.0% on the year before, operating income of −$115m (a -320.5% margin) and net income of −$105m, or −$1.27 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue463121363635
Research and development95118118111104100
General and administrative334342423636
Operating income−82−130−139−120−115−112
Income before tax−84−128−131−105−105—
Income tax001000
Net income−84−128−132−105−105−101
Diluted EPS−$1.82−$2.62−$2.67−$1.52−$1.27—
Diluted shares (average)46m49m50m69m83m—
EBITDA−81−128−137−118−113−110

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BHST vs CCCCCCCC vs VYGRCCCC vs FHTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from C4 Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to C4 Therapeutics, Inc.